UniQure snags May Day decision date for Huntington’s gene therapy after arduous year
After a year of controversial regulatory reversals, the FDA has accepted uniQure’s application for ifezuntirgene inilparvovec for priority review, with a May 1 action date. If approved, the therapy—also called AMT-130—would be the first disease-modifying treatment for Huntington’s disease.
UniQure snags May Day decision date for Huntington’s gene therapy after arduous year Read More »
